The document-intensive reality of drug development
Drug development is, at its core, a documentation enterprise. Every clinical trial generates a protocol, an investigator's brochure, informed consent forms, case report forms, statistical analysis plans, clinical study reports, and ultimately regulatory submission documents. A single New Drug Application (NDA) submitted to the FDA can contain over 100,000 pages.
The scientific and clinical work is essential and irreplaceable. But the documentation work — drafting, reviewing, cross-referencing, formatting, checking consistency — consumes a disproportionate share of the timeline. A clinical trial protocol amendment that changes eligibility criteria requires updates to the informed consent, the case report form, the randomisation plan, the statistical analysis plan, and potentially the investigator's brochure. Each update must be consistent across all documents.
This is where AI delivers value in drug development: not in making scientific decisions, but in accelerating the documentation, review, and processing workflows that surround those decisions. The scientists and clinicians focus on the science. AI handles the document processing at scale.
What type of organisation do you work in?
Clinical trial protocol analysis
A Phase III clinical trial protocol is typically 150-250 pages covering: study objectives, study design, eligibility criteria, treatment plan, study assessments, statistical methods, adverse event reporting, data management, quality assurance, and regulatory considerations. Over 60% of clinical trials experience at least one protocol amendment, often because of issues that could have been caught during the initial review.
Common issues that AI can systematically identify:
Eligibility criteria conflicts. Inclusion criterion #4 says "adults aged 18 and older," but the exclusion criteria reference a paediatric dosing schedule. The informed consent form says "participants aged 18-65," but the protocol has no upper age limit. These inconsistencies across a 200-page document are easy for human reviewers to miss but systematic for AI to catch.
Endpoint misalignment. The primary endpoint in the objectives section says "progression-free survival at 12 months," but the statistical analysis plan is powered for "overall survival at 24 months." The schedule of assessments does not include the imaging timepoints needed to assess progression-free survival.
Regulatory compliance gaps. The protocol references ICH E6(R2) Good Clinical Practice guidelines but omits required safety reporting timelines. The data monitoring committee charter does not align with the interim analysis schedule in the statistical plan.
ROLE: You are a clinical trial protocol reviewer with expertise in ICH-GCP
guidelines and FDA regulatory requirements.
SOURCE DATA: The following is a complete clinical trial protocol for a
[Phase I/II/III] study in [therapeutic area].
[Paste or attach the protocol document]
TASK: Conduct a systematic review of the protocol for:
1. INTERNAL CONSISTENCY:
- Do the eligibility criteria (inclusion/exclusion) contain any conflicts?
- Does the primary endpoint in the objectives match the primary endpoint
in the statistical analysis plan?
- Does the schedule of assessments include all timepoints needed to
evaluate the stated endpoints?
- Are dosing instructions consistent between the treatment plan and the
investigator's brochure summary?
- Does the informed consent form language align with the protocol procedures?
2. ELIGIBILITY CRITERIA ANALYSIS:
- Are criteria specific enough to be operationalised at study sites?
- Are there criteria that may unnecessarily restrict enrolment
(overly narrow age range, excessive exclusions for comorbidities)?
- Do criteria align with the target population described in the
study rationale?
- Are lab value thresholds for eligibility defined with specific units
and reference ranges?
3. REGULATORY ALIGNMENT:
- ICH E6(R2) GCP compliance: Are required elements present?
- Safety reporting: Are expedited reporting timelines for SAEs and
SUSARs clearly defined?
- Data monitoring: Is the DMC charter consistent with the interim
analysis schedule?
- Informed consent: Does the ICF include all elements required by
21 CFR 50.25?
4. OPERATIONAL FEASIBILITY:
- Are assessment schedules realistic for site staff?
- Are visit windows defined?
- Are procedures ordered logically within each visit?
OUTPUT: Issue list organised by severity:
- CRITICAL: Issues that could affect patient safety or regulatory acceptance
- MAJOR: Issues that could affect data quality or study conduct
- MINOR: Inconsistencies that should be corrected but are unlikely to
affect outcomes
For each issue, cite the specific protocol section and text where the
problem exists, and reference the conflicting section if applicable.This review typically takes a clinical operations team 2-3 weeks for a complex protocol. AI generates the initial findings in under an hour, giving the team a structured list to review, validate, and prioritise rather than reading the entire document from scratch.
Systematic literature review and evidence synthesis
Systematic literature reviews are among the most time-intensive activities in pharmaceutical development. A systematic review for a regulatory submission or health technology assessment (HTA) dossier requires: defining the search strategy (PICOS framework), screening thousands of abstracts, retrieving and reviewing full-text articles, extracting data into evidence tables, assessing quality and risk of bias, and synthesising findings.
A typical systematic review involves screening 2,000-5,000 abstracts, reviewing 100-300 full-text articles, and extracting data from 30-80 included studies. The manual process takes 3-6 months for a team of 2-3 medical writers or researchers.
AI accelerates every step except the scientific judgment calls:
ROLE: You are a medical writer conducting a systematic literature review for
a [regulatory submission / HTA dossier / publication / internal evidence assessment].
TASK 1 — ABSTRACT SCREENING:
Review the following abstracts against the inclusion/exclusion criteria below.
INCLUSION CRITERIA (PICOS):
- Population: [Define the patient population]
- Intervention: [Define the intervention of interest]
- Comparator: [Define acceptable comparators]
- Outcomes: [Define the outcomes of interest]
- Study design: [RCT / observational / meta-analysis / specify]
EXCLUSION CRITERIA:
- [List specific exclusion criteria: wrong population, wrong intervention,
case reports, animal studies, non-English language, etc.]
ABSTRACTS:
[Paste batch of abstracts with identifiers]
FOR EACH ABSTRACT, PROVIDE:
- Decision: INCLUDE / EXCLUDE / UNCERTAIN
- Reason: Brief explanation citing the specific criterion met or not met
- If UNCERTAIN: What additional information from the full text would resolve it
TASK 2 — DATA EXTRACTION (for included full-text articles):
Extract the following data points from each included study:
[Paste the data extraction form with fields:
Study ID / Author / Year / Design / Population N / Population characteristics /
Intervention details / Comparator details / Primary outcome definition /
Primary outcome results / Secondary outcomes / Safety findings / Risk of bias
assessment / Funding source / Key limitations]
OUTPUT FORMAT: Structured evidence table with one row per study and one
column per data extraction field. Flag any field where the data is not
reported or is ambiguous.The critical workflow principle: AI does the initial screening and extraction, but a human reviewer validates every inclusion/exclusion decision and every extracted data point. Dual-reviewer validation — standard in systematic review methodology — still applies. AI serves as one of the reviewers, with a human as the other.
How many systematic literature reviews does your organisation conduct per year?
FDA submission document review — NDA, BLA, and 510(k)
Regulatory submissions to the FDA are among the highest-stakes documents in the pharmaceutical industry. An NDA (New Drug Application) or BLA (Biologics License Application) represents years of development and billions of dollars of investment. A 510(k) submission for a medical device can determine whether a product reaches market. Errors, inconsistencies, or missing information can trigger FDA Refuse to File letters, Information Requests, or Complete Response Letters — each costing months of delay.
AI does not write regulatory submissions. Regulatory affairs professionals, medical writers, and clinical scientists produce the content. AI reviews the assembled submission for the kinds of errors that human reviewers miss when working across hundreds of pages:
ROLE: You are a regulatory affairs specialist reviewing a [NDA/BLA/510(k)]
submission package for internal quality control before filing with the FDA.
SOURCE DATA: The following sections of the submission package:
[List the modules/sections provided — e.g., Module 2.5 Clinical Overview,
Module 2.7 Clinical Summary, Module 5 Clinical Study Reports]
TASK: Review the submission for:
1. INTERNAL CONSISTENCY:
- Do efficacy results cited in the Clinical Overview (Module 2.5) match
the results tables in the Clinical Study Reports (Module 5)?
- Are adverse event frequencies consistent between the safety summary
and the individual study reports?
- Is the proposed indication wording consistent across the Clinical
Overview, the prescribing information/labelling, and the cover letter?
- Do patient population descriptions match across modules?
2. CROSS-REFERENCE INTEGRITY:
- Are all cross-references to tables, figures, and appendices valid?
- Do section references point to the correct location?
- Are study identifiers (protocol numbers, NCT numbers) consistent
throughout?
3. REGULATORY FORMAT COMPLIANCE:
- Does the structure follow the current eCTD (electronic Common Technical
Document) format requirements?
- Are all required sections present per [relevant FDA guidance document]?
- Do safety reporting tables follow the FDA's preferred format for
adverse event presentation?
4. COMPLETENESS CHECK:
- Are there any sections referenced in the table of contents that
are missing from the submission?
- Are all required patient narratives included for SAEs and deaths?
- Is the environmental assessment or claim of categorical exclusion
included?
OUTPUT: Issue list with:
- Section and page reference where the issue occurs
- Description of the inconsistency or gap
- Severity: FILING RISK (could trigger Refuse to File) / QUALITY (should
be corrected before filing) / MINOR (cosmetic or formatting)
- Suggested resolutionA single pass of this review across a major NDA submission can identify dozens of inconsistencies that would otherwise be caught by FDA reviewers — triggering Information Requests that delay the review timeline by months.
Adverse event report processing — pharmacovigilance
Pharmacovigilance — the science of detecting, assessing, understanding, and preventing adverse effects of medicines — generates one of the highest-volume documentation workflows in pharma. Individual Case Safety Reports (ICSRs) arrive from multiple sources: healthcare providers, patients, clinical trials, published literature, and regulatory databases.
A major pharmaceutical company may process 200,000-500,000 ICSRs per year. Each report must be triaged, data-entered into the safety database, medically reviewed, assessed for seriousness and expectedness, coded using MedDRA (Medical Dictionary for Regulatory Activities), and evaluated for regulatory reporting obligations.
The regulatory timelines are strict: serious and unexpected adverse events must be reported to regulatory authorities within 15 calendar days (or 7 days for fatal/life-threatening events in clinical trials). Missing a reporting deadline is a serious regulatory violation.
ROLE: You are a pharmacovigilance case processor reviewing an incoming Individual
Case Safety Report (ICSR).
SOURCE DATA: The following is an adverse event report received via
[healthcare provider / patient / literature / regulatory database].
[Paste the adverse event report text]
TASK:
1. CASE INTAKE: Extract the following fields from the report:
- Reporter information (type: HCP/patient/other, country)
- Patient demographics (age, sex, relevant medical history if reported)
- Suspect product(s) (name, dose, route, indication, start/stop dates)
- Adverse event(s) (verbatim term as reported)
- Event onset date and outcome (resolved, ongoing, fatal, unknown)
- Seriousness criteria: Does the event meet any ICH E2D seriousness criteria?
(death, life-threatening, hospitalisation, disability, congenital anomaly,
medically important event)
- Dechallenge/rechallenge information if reported
2. MedDRA CODING: Suggest the appropriate MedDRA Preferred Term(s) for each
reported adverse event. Provide the verbatim term, the suggested PT, and
the SOC (System Organ Class).
3. EXPECTEDNESS ASSESSMENT: Based on the product's current labelling/SmPC/IB:
[Provide the relevant safety reference document]
- Is the event listed in the current safety reference? (Expected/Unexpected)
- If unexpected, flag for expedited regulatory reporting
4. REGULATORY REPORTING TRIAGE:
- Is this case subject to expedited reporting? (Serious + Unexpected = Yes)
- What is the reporting deadline? (15-day for serious unexpected, 7-day
for fatal/life-threatening in clinical trials)
- Which regulatory authorities require notification based on the
reporter country and marketing authorisation geography?
5. QUALITY CHECK:
- Is the report valid (identifiable reporter, identifiable patient,
suspect product, adverse event)?
- What information is missing that should be followed up with the reporter?
OUTPUT: Structured case summary with all fields populated, regulatory
reporting recommendation, and follow-up action items.This workflow does not replace the medical reviewer who makes the final causality assessment and the pharmacovigilance scientist who evaluates the signal. It accelerates the case processing step — extracting data, coding events, and triaging for regulatory deadlines — so that human experts spend their time on the medical and scientific evaluation rather than data entry.
What is the primary pharmacovigilance challenge in your organisation?
Regulatory intelligence monitoring and competitive pipeline analysis
Beyond specific document workflows, AI is valuable for two strategic intelligence functions in life sciences: monitoring the regulatory landscape and tracking the competitive pipeline.
Regulatory intelligence monitoring means staying current with FDA draft guidances, EMA scientific guidelines, ICH harmonisation updates, and country-specific regulatory changes that affect your development programmes. A single missed guidance update can result in a submission that does not align with current regulatory expectations.
ROLE: You are a regulatory intelligence analyst monitoring regulatory developments
for a [therapeutic area] drug development programme.
TASK: Review the following regulatory documents and provide a structured
intelligence briefing:
[Paste or reference recent FDA guidance documents, Federal Register notices,
EMA committee meeting minutes, or ICH guidelines]
FOR EACH DOCUMENT:
1. SUMMARY: 3-5 sentence summary of the key regulatory development
2. IMPACT ASSESSMENT: How does this affect our [specific development programme]:
- Does it change requirements for clinical trial design?
- Does it affect submission requirements or review pathways?
- Does it introduce new safety monitoring or reporting obligations?
- Does it affect our competitive position (e.g., new accelerated
pathway that a competitor could use)?
3. ACTION ITEMS: What should the regulatory affairs team do in response?
- Immediate actions (within 30 days)
- Planning actions (within 90 days)
- Monitoring actions (ongoing watch items)
4. CROSS-REFERENCE: Which other programmes in our portfolio are affected
by the same regulatory development?Competitive pipeline analysis involves tracking competing drugs in development: what stage they are at, what their trial designs look like, what regulatory interactions they have had, and what their expected timelines are. This information comes from ClinicalTrials.gov, FDA review documents, conference presentations, and company press releases.
ROLE: You are a competitive intelligence analyst in a pharmaceutical company.
TASK: Based on the following data sources, provide a competitive landscape
analysis for [therapeutic area / indication]:
SOURCES:
[ClinicalTrials.gov listings, FDA approval letters, conference abstracts,
company press releases, analyst reports]
ANALYSIS:
1. PIPELINE MAP: List all known compounds in development for [indication],
organised by development phase (Preclinical / Phase I / II / III / Filed / Approved)
2. For each competitor:
- Mechanism of action
- Current development stage and estimated timeline to market
- Trial design summary (population, primary endpoint, comparator)
- Differentiation vs our compound (efficacy, safety, dosing, route)
- Regulatory strategy (standard review, priority review, breakthrough
designation, accelerated approval)
3. RISK ASSESSMENT: Which competitors pose the greatest threat to our
market position and why?
4. OPPORTUNITY IDENTIFICATION: Are there underserved patient subpopulations
or combination opportunities that competitors are not pursuing?These strategic intelligence workflows transform information monitoring from a reactive, ad-hoc process into a systematic capability that keeps development teams informed and decision-ready.
Module 4 — Final Assessment
01What is the primary value of AI in clinical trial protocol review?
02In a systematic literature review, what role does AI play vs the human reviewer?
03Why is AI triage of ICSRs critical for pharmacovigilance compliance?
04What should an AI review of an NDA/BLA submission focus on?